“Heading into 1Q25, we also believe BPMC could be seen as an attractive target for strategic partnerships, which could boost shares,” JP Morgan writes. With Ayvakit’s launch being a major focus for ...

For families already under immense stress, the added burden of sourcing medications outside, coupled with the financial ...